Company Updates

Peppermint Letter to Shareholders 2016 Annual Report

29th August 2016, Money Management By Jessica Amir Investors might be missing out on attractive returns and opportunities, which a lot of brokers are unaware of, unless investors have some exposure to quantitative style funds, according to Meme Capital Management. Meme Capital’s chief investment officer, Greg Jude, employed quantitative analysis to pick ex-ASX top 20 […]

26th August 2016, ASX Announcement Window On The Science – Proteins in medicine  A revolution in medicine is well underway, underpinned by the desire for a deeper understanding of the basis of disease beyond that of classical pathology. Determining what is happening at the molecular level can guide treatment of diseases with precision. At its […]

29th august 2016, ASX Announcement Highlights Aeeris has secured two important new contracts for deployment of its recently developed SecureAMS(Secure Access Management System) technology. New Marketing Partnership Agreement with Australian Security Technology (AST) to jointly promote and sell theSecureAMS solution to AST customers in Australia. Background to SecureAMS SecureAMS is a unique and ground-breaking technology […]

Alcidion to Host Investor Webinar on 31 August 2016

29th august 2016, NBR By Jonathan Underhill Spotlight Reporting, which provides cloud-based tools to import data from accounting service firms such as Xero and QuickBooks to generate reports, forecasts and dashboards, says it raised $5 million from an NZVIF-backed fund, Vend’s David Wilson and Xero director Graig Winkler among others. The Wellington-based company says chief […]

ABOUT QBIOTICS QBiotics Limited is developing a pipeline of promising drugs in the area of cancer and wound healing. Its lead drug, EBC-46, targets solid tumours and is currently in late pre-clinical development in preparation for a Human Clinical Phase I/II trial with the USA’s FDA. EBC-46 is also in late stage development for the […]

26th August 2016, ASX Announcement Highlights Revenue from pharmacy subscriptions and patient engagement programs (PEP) has grown by ~24% to $1.43 million, driven primarily by pharmacy subscription growth Total revenue of $1.76m is 7% lower compared to FY15 which included the final licence fee payment $500,00 under the Actavis agreement Gross margin from pharmacy subscriptions […]

25th August 2016, Proactive Investors Altech Chemicals Ltd (ASX:ATC) has received a Speculative Buy from Perth-based stockbroking firm DJ Carmichael. The broker applied a valuation of $0.355 from $0.41 per share. The following is an extract from the report. ECA financing steps in final throws ATC are making good progress on their project funding application […]